Cargando…

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice

The cytokine interleukin-1β (IL-1β) is known to stimulate proinflammatory immune responses and impair β-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1β receptor antagonist, on diabetes progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Cucak, Helena, Hansen, Gitte, Vrang, Niels, Skarsfeldt, Torben, Steiness, Eva, Jelsing, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756207/
https://www.ncbi.nlm.nih.gov/pubmed/26953152
http://dx.doi.org/10.1155/2016/7484601
_version_ 1782416288624148480
author Cucak, Helena
Hansen, Gitte
Vrang, Niels
Skarsfeldt, Torben
Steiness, Eva
Jelsing, Jacob
author_facet Cucak, Helena
Hansen, Gitte
Vrang, Niels
Skarsfeldt, Torben
Steiness, Eva
Jelsing, Jacob
author_sort Cucak, Helena
collection PubMed
description The cytokine interleukin-1β (IL-1β) is known to stimulate proinflammatory immune responses and impair β-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1β receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1β activated pathways.
format Online
Article
Text
id pubmed-4756207
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-47562072016-03-07 The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice Cucak, Helena Hansen, Gitte Vrang, Niels Skarsfeldt, Torben Steiness, Eva Jelsing, Jacob J Diabetes Res Research Article The cytokine interleukin-1β (IL-1β) is known to stimulate proinflammatory immune responses and impair β-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1β receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1β activated pathways. Hindawi Publishing Corporation 2016 2016-02-03 /pmc/articles/PMC4756207/ /pubmed/26953152 http://dx.doi.org/10.1155/2016/7484601 Text en Copyright © 2016 Helena Cucak et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cucak, Helena
Hansen, Gitte
Vrang, Niels
Skarsfeldt, Torben
Steiness, Eva
Jelsing, Jacob
The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
title The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
title_full The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
title_fullStr The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
title_full_unstemmed The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
title_short The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
title_sort il-1β receptor antagonist ser140 postpones the onset of diabetes in female nonobese diabetic mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756207/
https://www.ncbi.nlm.nih.gov/pubmed/26953152
http://dx.doi.org/10.1155/2016/7484601
work_keys_str_mv AT cucakhelena theil1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT hansengitte theil1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT vrangniels theil1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT skarsfeldttorben theil1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT steinesseva theil1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT jelsingjacob theil1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT cucakhelena il1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT hansengitte il1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT vrangniels il1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT skarsfeldttorben il1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT steinesseva il1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice
AT jelsingjacob il1breceptorantagonistser140postponestheonsetofdiabetesinfemalenonobesediabeticmice